-
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
16 Apr 2024 15:01 GMT
In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B). …
-
Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript
25 Jan 2024 14:40 GMT
Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript January 23, 2024
Johnson & Johnson beats earnings expectations. Reported EPS is $2.29, expectations were $2.27. Johnson & Johnson isn’t one of the 30 most popular stocks among hedge …
-
Johnson & Johnson reports robust quarter, but full-year earnings slip
24 Jan 2024 01:04 GMT
Adjusted earnings per share for the quarter came in at $2.29, surpassing expectations by a narrow margin.
For the full year, Johnson & Johnson reported sales of $85.2bn, representing a 6.5% growth rate.
However, full-year earnings per share decreased …
-
Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
23 Jan 2024 12:40 GMT
The stock trading graph of Johnson & Johnson is seen on a smartphone screen.
Rafael Henrique | SOPA Images | LightRocket | Getty Images
Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street…
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
23 Jan 2024 11:33 GMT
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” …
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
23 Jan 2024 11:24 GMT
Market Closed -
Nyse
04:00:02 2024-01-22 pm EST
5-day change
1st Jan Change
162.47
USD
+0.49%
+0.05%
+3.66%
Official JOHNSON & JOHNSON press release
January 23, 2024 at 06:21 am EST
2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion …
-
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027 from BioPharma-Reporter.com
25 Apr 2024 20:04 GMT
While the PARP inhibitors market has seen increasing competition over the years, Lynparza is set to remain dominant – with GlobalData projecting global sales of $4 billion by 2027 for the drug.
According to the data and analytics firm, this high sales …
-
Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript
18 Oct 2023 13:12 GMT
Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript October 17, 2023
Operator: Good morning, and welcome to Johnson & Johnson’s Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question …
-
Johnson & Johnson Reports Q3 2023 Results
17 Oct 2023 10:26 GMT
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2023. “Johnson & Johnson delivered strong results and significant pipeline advances in the third quarter, providing a solid foundation for future sustained growth,” said …
-
Johnson & Johnson : Consolidated Financial Statements - Form 8-K
24 Jul 2023 11:07 GMT
The following are certain preliminary results of selected unaudited financial and other information of Johnson & Johnson for the fiscal three and six months ended July 2, 2023 and actual unaudited financial results of Johnson & Johnson for the …